4164:TADAWULNahdi Medical Company Analysis

Nahdi Medical Company trades above its discounted cash‑flow estimate, indicating the market is pricing in a premium despite a solid dividend yield. Technical signals are mixed: the RSI sits in the upper half of its range, the MACD remains bullish, and the price is above the short‑term moving averages but still below the long‑term average, suggesting a neutral to slightly positive momentum.
The fundamentals are compelling – earnings growth, a return on equity above 30%, and a dividend yield that ranks among the higher in the Saudi market – yet the company carries a relatively high debt load and an almost ninety‑percent payout ratio, raising questions about dividend sustainability. The low beta and extreme‑greed market sentiment temper the volatility risk, but the decreasing volume and elevated 30‑day price swings add a cautionary note.